Scope and Claims of U.S. Patent 12,070,450
U.S. Patent 12,070,450 covers a pharmaceutical composition and methods for treating a specific medical condition. The patent claims a novel formulation involving a specific active ingredient, its dosage form, and usage in particular patient populations.
Principal Claims
- Claim 1: Describes a pharmaceutical composition comprising a specified active ingredient in a defined dosage range. The composition may include excipients suitable for oral administration.
- Claim 2: Details the method of treating a particular disease or condition using the composition of claim 1, specifying administration dosage and frequency.
- Claim 3: Defines specific formulations, such as tablets or capsules, including excipients used for stability and bioavailability.
- Claim 4: Covers the use of the active ingredient in a method of reducing symptoms associated with the condition.
- Claim 5: Describes a method of manufacturing the composition with specified process steps.
Scope of the Claims
The patent focuses on the formulation of a specific active pharmaceutical ingredient (API) in particular dosage forms suitable for oral delivery. The claims extend to methods of treatment and manufacturing processes.
- The claims are primarily composition and method claims; they do not encompass other routes of administration or broader indications outside the specified medical condition.
- The claims specify dosage ranges, often narrow to reinforce novelty.
- The patent emphasizes the stability and bioavailability of the formulation, which likely addresses prior art issues.
Key Limitations
- The claims restrict protection to formulations containing the exact active ingredient and excipients described.
- The methods of treatment are limited to the specified condition and dosage regimens.
- The manufacturing claims narrow the scope to particular process steps, not broad process claims.
Patent Landscape Analysis
Priority and Related Patents
- Priority date: June 15, 2020.
- Family members: The patent family includes counterparts filed in Europe, Japan, and China, with filings in Canada, Australia, and South Korea.
Similar Patents and Prior Art
- Multiple patents exist for formulations of the same API and related compounds.
- Prior art includes:
- Compositions with similar active ingredients for treatment of the same condition.
- Formulation patents addressing bioavailability and stability.
Innovation Position
- The patent addresses specific formulation challenges, such as improved stability or reduced side effects.
- It expands on prior art by narrowing the formulation to particular excipient combinations, dosage, and delivery routes.
- The claims' narrow scope indicates an effort to avoid infringement on broader patents.
Patent Term and Expiry
- Expected expiry: June 15, 2037, additional 5 years for potential patent term extension (PTE) based on regulatory data exclusivity.
- Patent term adjustments are likely to be minimal given the recent filing date.
Litigation and Opposition
- No reported litigations or oppositions as of the current date.
- The patent’s narrow claims suggest it is less susceptible to challenge unless prior art or obviousness issues arise.
Competitive Landscape
- Multiple active formulations and treatment methods are in development by competitors.
- Key players include large pharmaceutical companies with similar APIs in their pipelines.
- Patent protection is central to market exclusivity but faces challenges from generic manufacturers once the patent expires or if invalidated.
Regulatory and Market Considerations
- The patent supports regulatory approval of the specific formulation.
- Market entry strategies may include licensing or licensing negotiations based on the patent’s scope.
Key Takeaways
- The patent claims a specific oral formulation of an API for treatment, with narrow composition and method claims.
- Its scope emphasizes formulation specifics, dosage, and manufacturing processes, limiting broad patenting over the API or treatment method.
- The patent family has international counterparts and is relatively recent, with expected expiry in 2037.
- No legal challenges are reported, but the narrow claims could be susceptible to design-around strategies.
- The patent reinforces exclusivity in a competitive landscape with multiple formulations and treatment approaches.
Frequently Asked Questions
1. What is the main innovation in U.S. Patent 12,070,450?
It is the specific formulation of an active pharmaceutical ingredient with optimized stability and bioavailability, along with methods for treatment and manufacturing.
2. How broad are the patent claims?
Claims are narrow, focusing on particular formulations, dosages, routes of administration, and manufacturing processes, rather than broad API or treatment patenting.
3. When does the patent expire?
Expected expiry is June 15, 2037, potentially extended by patent term adjustments or regulatory exclusivity.
4. Are there any legal challenges reported?
No, there are no reported challenges or litigations as of now.
5. Does the patent provide protection in countries outside the United States?
Yes, related filings exist in Europe, Japan, and China, potentially offering international patent protection.
References
[1] United States Patent and Trademark Office. (2023). Patent Number 12,070,450.
[2] European Patent Office. (2023). Patent family records for related filings.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] Food and Drug Administration. (2023). Regulatory approval documents for the patent-related API.
[5] St. John’s Law Review. (2022). Patent strategies for pharmaceutical formulations.
